[Clinico-microbiologic bases for the use of new cephalosporins].
D001419:Bacteria / Q000187:drug effects*; D001439:Bacteroides / Q000187:drug effects; D002435:Cefamandole / Q000494:pharmacology; D002440:Cefoxitin / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology* / Q000627:therapeutic use; D002512:Cephalothin / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D006801:Humans; D010460:Peptococcus / Q000187:drug effects; D010462:Peptostreptococcus / Q000187:drug effects; D011549:Pseudomonas / Q000187:drug effects; D065093:beta-Lactamase Inhibitors
D002511:Cephalosporins; D065093:beta-Lactamase Inhibitors; D002435:Cefamandole; D002440:Cefoxitin; D002444:Cefuroxime; D002512:Cephalothin
Basi clinico-microbiologiche dell'uso di nuove cefalosporine.